Neurones S.A. Logo

Neurones S.A.

NRO.PA

(3.5)
Stock Price

45,10 EUR

7.95% ROA

14.42% ROE

22.05x PER

Market Cap.

1.080.207.418,00 EUR

12.41% DER

2.7% Yield

6.67% NPM

Neurones S.A. Stock Analysis

Neurones S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Neurones S.A. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (11%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Net Profit Growth

This company has consistently achieved strong net profit growth over the past five years, demonstrating a solid financial performance and making it an appealing investment option.

4 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

6 ROE

ROE in an average range (9.3%) suggests satisfactory profitability and decent utilization of shareholders' equity.

7 ROA

The stock's ROA (3.85%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

8 PBV

The stock's PBV ratio (2.73x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

9 Buffet Intrinsic Value

The company's stock seems undervalued (647) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Neurones S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Neurones S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Neurones S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Neurones S.A. Revenue
Year Revenue Growth
2002 92.623.000
2003 92.732.000 0.12%
2004 97.098.000 4.5%
2005 108.920.000 10.85%
2006 129.967.000 16.19%
2007 155.977.000 16.68%
2008 189.328.000 17.62%
2009 216.390.000 12.51%
2010 239.568.000 9.67%
2011 283.311.000 15.44%
2012 315.402.000 10.17%
2013 343.165.000 8.09%
2014 355.170.000 3.38%
2015 399.368.000 11.07%
2016 446.760.000 10.61%
2017 485.014.000 7.89%
2018 490.075.000 1.03%
2019 510.074.000 3.92%
2020 524.489.000 2.75%
2021 579.879.000 9.55%
2022 665.379.000 12.85%
2023 1.489.932.000 55.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Neurones S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Neurones S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 54.207.000
2003 55.841.000 2.93%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 44.019.000 100%
2009 50.089.000 12.12%
2010 53.201.000 5.85%
2011 5.296.000 -904.55%
2012 66.770.000 92.07%
2013 78.576.000 15.02%
2014 78.363.000 -0.27%
2015 98.299.000 20.28%
2016 116.277.000 15.46%
2017 133.559.000 12.94%
2018 142.086.000 6%
2019 143.466.000 0.96%
2020 150.723.000 4.81%
2021 170.823.000 11.77%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Neurones S.A. EBITDA
Year EBITDA Growth
2002 81.355.000
2003 84.399.000 3.61%
2004 9.453.000 -792.83%
2005 10.355.000 8.71%
2006 11.442.000 9.5%
2007 15.428.000 25.84%
2008 24.814.000 37.83%
2009 22.688.000 -9.37%
2010 28.509.000 20.42%
2011 31.933.000 10.72%
2012 33.863.000 5.7%
2013 37.026.000 8.54%
2014 40.357.000 8.25%
2015 42.456.000 4.94%
2016 50.451.000 15.85%
2017 52.733.000 4.33%
2018 53.708.000 1.82%
2019 63.592.000 15.54%
2020 66.075.000 3.76%
2021 75.274.000 12.22%
2022 86.329.000 12.81%
2023 175.632.000 50.85%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Neurones S.A. Gross Profit
Year Gross Profit Growth
2002 81.877.000
2003 84.993.000 3.67%
2004 90.436.000 6.02%
2005 101.141.000 10.58%
2006 122.958.000 17.74%
2007 147.032.000 16.37%
2008 180.191.000 18.4%
2009 208.103.000 13.41%
2010 50.072.000 -315.61%
2011 33.988.000 -47.32%
2012 103.935.000 67.3%
2013 119.377.000 12.94%
2014 120.306.000 0.77%
2015 142.986.000 15.86%
2016 166.206.000 13.97%
2017 186.089.000 10.68%
2018 197.983.000 6.01%
2019 56.705.000 -249.15%
2020 68.609.000 17.35%
2021 69.735.000 1.61%
2022 81.635.000 14.58%
2023 170.792.000 52.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Neurones S.A. Net Profit
Year Net Profit Growth
2002 5.958.000
2003 4.858.000 -22.64%
2004 5.423.000 10.42%
2005 5.927.000 8.5%
2006 6.141.000 3.48%
2007 9.946.000 38.26%
2008 12.976.000 23.35%
2009 12.815.000 -1.26%
2010 14.938.000 14.21%
2011 17.039.000 12.33%
2012 14.849.000 -14.75%
2013 18.570.000 20.04%
2014 20.505.000 9.44%
2015 21.358.000 3.99%
2016 25.199.000 15.24%
2017 27.310.000 7.73%
2018 25.959.000 -5.2%
2019 30.799.000 15.71%
2020 30.918.000 0.38%
2021 37.706.000 18%
2022 44.243.000 14.78%
2023 95.956.000 53.89%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Neurones S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1 0%
2009 0 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 100%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 2 0%
2022 2 0%
2023 4 66.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Neurones S.A. Free Cashflow
Year Free Cashflow Growth
2002 -835.847
2003 7.182 11738.08%
2004 6.372.000 99.89%
2005 4.748.000 -34.2%
2006 2.237.000 -112.25%
2007 12.977.000 82.76%
2008 14.393.000 9.84%
2009 13.410.000 -7.33%
2010 12.681.000 -5.75%
2011 3.408.000 -272.1%
2012 14.743.000 76.88%
2013 14.520.000 -1.54%
2014 23.294.000 37.67%
2015 17.205.000 -35.39%
2016 12.549.000 -37.1%
2017 14.312.000 12.32%
2018 24.113.000 40.65%
2019 53.552.000 54.97%
2020 61.797.000 13.34%
2021 58.105.000 -6.35%
2022 44.333.000 -31.06%
2023 34.867.000 -27.15%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Neurones S.A. Operating Cashflow
Year Operating Cashflow Growth
2002 6.153
2003 8.193 24.9%
2004 7.514.000 99.89%
2005 5.581.000 -34.64%
2006 4.208.000 -32.63%
2007 15.345.000 72.58%
2008 16.710.000 8.17%
2009 15.600.000 -7.12%
2010 15.498.000 -0.66%
2011 8.297.000 -86.79%
2012 19.240.000 56.88%
2013 20.023.000 3.91%
2014 28.602.000 29.99%
2015 30.052.000 4.82%
2016 21.101.000 -42.42%
2017 23.268.000 9.31%
2018 31.062.000 25.09%
2019 61.440.000 49.44%
2020 68.989.000 10.94%
2021 64.684.000 -6.66%
2022 54.938.000 -17.74%
2023 46.883.000 -17.18%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Neurones S.A. Capital Expenditure
Year Capital Expenditure Growth
2002 842.000
2003 1.011 -83183.88%
2004 1.142.000 99.91%
2005 833.000 -37.09%
2006 1.971.000 57.74%
2007 2.368.000 16.77%
2008 2.317.000 -2.2%
2009 2.190.000 -5.8%
2010 2.817.000 22.26%
2011 4.889.000 42.38%
2012 4.497.000 -8.72%
2013 5.503.000 18.28%
2014 5.308.000 -3.67%
2015 12.847.000 58.68%
2016 8.552.000 -50.22%
2017 8.956.000 4.51%
2018 6.949.000 -28.88%
2019 7.888.000 11.9%
2020 7.192.000 -9.68%
2021 6.579.000 -9.32%
2022 10.605.000 37.96%
2023 12.016.000 11.74%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Neurones S.A. Equity
Year Equity Growth
2002 52.893.000
2003 57.398.000 7.85%
2004 64.702.000 11.29%
2005 70.652.000 8.42%
2006 76.513.000 7.66%
2007 82.635.000 7.41%
2008 96.912.000 14.73%
2009 108.276.000 10.5%
2010 121.327.000 10.76%
2011 139.127.000 12.79%
2012 155.418.000 10.48%
2013 175.209.000 11.3%
2014 196.874.999 11%
2015 215.748.000 8.75%
2016 238.455.000 9.52%
2017 268.053.000 11.04%
2018 295.875.999 9.4%
2019 327.322.000 9.61%
2020 359.025.000 8.83%
2021 352.919.000 -1.73%
2022 376.076.000 6.16%
2023 407.907.000 7.8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Neurones S.A. Assets
Year Assets Growth
2002 78.872.000
2003 82.278.000 4.14%
2004 93.069.000 11.59%
2005 100.847.000 7.71%
2006 118.258.000 14.72%
2007 135.477.000 12.71%
2008 165.637.000 18.21%
2009 169.048.000 2.02%
2010 189.963.000 11.01%
2011 225.466.000 15.75%
2012 249.997.000 9.81%
2013 278.716.000 10.3%
2014 304.168.000 8.37%
2015 351.196.000 13.39%
2016 385.631.000 8.93%
2017 411.694.000 6.33%
2018 449.056.000 8.32%
2019 510.138.000 11.97%
2020 549.851.000 7.22%
2021 567.823.000 3.17%
2022 617.241.000 8.01%
2023 674.251.000 8.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Neurones S.A. Liabilities
Year Liabilities Growth
2002 24.758.000
2003 23.318.000 -6.18%
2004 28.367.000 17.8%
2005 30.195.000 6.05%
2006 41.745.000 27.67%
2007 49.587.000 15.81%
2008 68.725.000 27.85%
2009 60.772.000 -13.09%
2010 68.636.000 11.46%
2011 86.339.000 20.5%
2012 94.579.000 8.71%
2013 103.507.000 8.63%
2014 107.293.000 3.53%
2015 135.448.000 20.79%
2016 147.176.000 7.97%
2017 143.641.000 -2.46%
2018 153.180.000 6.23%
2019 182.816.000 16.21%
2020 190.826.000 4.2%
2021 214.904.000 11.2%
2022 241.165.000 10.89%
2023 266.344.000 9.45%

Neurones S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
30.28
Net Income per Share
2.02
Price to Earning Ratio
22.05x
Price To Sales Ratio
1.46x
POCF Ratio
14.73
PFCF Ratio
19.3
Price to Book Ratio
3.07
EV to Sales
1.12
EV Over EBITDA
9.6
EV to Operating CashFlow
11.18
EV to FreeCashFlow
14.77
Earnings Yield
0.05
FreeCashFlow Yield
0.05
Market Cap
1,08 Bil.
Enterprise Value
0,83 Bil.
Graham Number
25.64
Graham NetNet
18.39

Income Statement Metrics

Net Income per Share
2.02
Income Quality
1.5
ROE
0.14
Return On Assets
0.07
Return On Capital Employed
0.16
Net Income per EBT
0.62
EBT Per Ebit
1.08
Ebit per Revenue
0.1
Effective Tax Rate
0.26

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.12
Operating Profit Margin
0.1
Pretax Profit Margin
0.11
Net Profit Margin
0.07

Dividends

Dividend Yield
0.03
Dividend Yield %
2.7
Payout Ratio
0.54
Dividend Per Share
1.2

Operating Metrics

Operating Cashflow per Share
3.02
Free CashFlow per Share
2.29
Capex to Operating CashFlow
0.24
Capex to Revenue
0.02
Capex to Depreciation
1.13
Return on Invested Capital
0.14
Return on Tangible Assets
0.08
Days Sales Outstanding
115.47
Days Payables Outstanding
30.89
Days of Inventory on Hand
0.5
Receivables Turnover
3.16
Payables Turnover
11.82
Inventory Turnover
733.93
Capex per Share
0.73

Balance Sheet

Cash per Share
22,08
Book Value per Share
16,66
Tangible Book Value per Share
14.5
Shareholders Equity per Share
14.48
Interest Debt per Share
1.82
Debt to Equity
0.12
Debt to Assets
0.07
Net Debt to EBITDA
-2.95
Current Ratio
2.38
Tangible Asset Value
0,36 Bil.
Net Current Asset Value
0,28 Bil.
Invested Capital
428478000
Working Capital
0,32 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,23 Bil.
Average Payables
0,05 Bil.
Average Inventory
1674000
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Neurones S.A. Dividends
Year Dividends Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 2 100%
2022 1 -100%
2023 1 0%
2024 1 0%

Neurones S.A. Profile

About Neurones S.A.

Neurones S.A., an information technology (IT) services company, provides infrastructure, application, and consulting services in France and internationally. Its infrastructure services include infrastructure management, clouds, user support, DevOps, cybersecurity, IT service management, information system governance, and automation. The company also provides application services in the areas of SAP integration and outsourcing; mobility, data, IoT, digital, agile, UX/UI, and DevOps; IT consulting for finance, big data, AI and blockchain; content management, business process management, paperless process; and IT training and working with change management. In addition, it offers consulting services, including management and digital transformation, and digital marketing consulting; digital transformation services in the areas of agile/scrum, DevOps, CI/CD, cloud, infrastructure as code, cyber security, analytics, big data, mobility, digital workplace, connected devices, innovations, client experience, UX/UI, and digital marketing, as well as internal process digitization, ECM/BPM, RPA, dematerialization, AI, predictive maintenance, machine learning, and blockchain; and managed services/outsourcing services. The company serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technologies/media/telecoms, industry/public works and civil engineering, and public sector markets. Neurones S.A. was founded in 1984 and is headquartered in Nanterre, France.

CEO
Mr. Luc de Chammard
Employee
6.849
Address
Immeuble “le Clemenceau 1”
Nanterre, 92024

Neurones S.A. Executives & BODs

Neurones S.A. Executives & BODs
# Name Age
1 Paul-César Bonnel
Administrative & Financial director
70
2 Mr. Luc de Chammard
Chairman, Chief Executive Officer & Chief Information Officer
70
3 Mr. Bertrand Ducurtil
Chief Operating Officer, Executive Vice President, Deputy Chief Executive Officer & Director
70
4 Matthieu Vautier
Chief Marketing Officer
70

Neurones S.A. Competitors

SII S.A. Logo
SII S.A.

SII.PA

(3.2)
Infotel SA Logo
Infotel SA

INF.PA

(2.8)
Precia S.A. Logo
Precia S.A.

PREC.PA

(2.5)
IT Link SA Logo
IT Link SA

ALITL.PA

(2.2)